The Cure Xchange Challenge will award up to five winning teams one-year residencies at Cure in the heart of New York City and seed money, from a shared prize pool of up to $1 million, which includes unrestricted funding and in-kind resources, including space, advising and support programming. Winners will have mentors from among Cure’s executive advisory board and connections with world leaders, renowned entrepreneurs, public health experts and executives. Cure is collaborating with MIT Solve to operationalize the competition.
“We are excited to be launching this challenge and looking forward to welcoming the winning teams to Cure. As part Cure’s ecosystem, they will have the resources, experts, and network to support them as they develop AI-driven concepts, prototypes, or initial solutions through the exchange of ideas and collaboration of talents,” said Seema Kumar, Chief Executive Officer of Cure.
An advisory board of experts, selected in collaboration with MIT Solve, will choose finalists in November 2023 from among the applicants for a pitch competition in December 2023. These finalists will be judged by advisors with world renowned expertise, such as Richard Bright, Ph.D., Former Director of the Biomedical Advanced Research and Development Authority (BARDA), Strategic Advisor to Cure and Board Member of FIND; Mary Woolley, President and CEO of Research!America; and John Mattison, former Chief Medical Information Officer of Kaiser Permanente and now CMIO at Arsenal Capital Partners, among many more. Cure will announce the winning teams in January 2024.
The Cure Xchange Challenge: Health AI for Good is the inaugural challenge in a series that Cure is developing to foster and improve cross-disciplinary health innovation to address urgent health concerns without actionable curative solutions, such as Alzheimer’s and neurological disease, rare illnesses, pandemic preparedness and public trust in science.
Applications for the Cure Xchange Challenge: Health AI for Good are open to U.S.-based applicants who are able to participate in a one-year New York City residency starting in February 2023. Applications may be submitted as of September 12, 2023 via Cure or MIT Solve, which also offer the selection criteria, timeline, FAQ, and eligibility requirements. Applications are open to early-stage individuals or teams working at the concept, prototype or pilot stage of their AI solutions. Winners will retain intellectual property rights to their solutions.
MEDICA-tradefair.com; Source: ISC Intelligence in Science
